AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20660503 — intervention group
Group type: EXPERIMENTAL
Intervention: LLHA made of 1.25 mm SS wire
Number of subjects: 44
Study 20660503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLHA)
Number of subjects: 44
Study 19351624 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg infliximab every 8 weeks (arm A)
Number of subjects: 141
Study 19351624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab every 8 weeks (arm B)
Number of subjects: 141
Study 16719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multinutrient energy‐dense oral supplement (6.3 kJ/mL) for six weeks
Number of subjects: 100
Study 16719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri‐weekly resistance training for 12 weeks
Number of subjects: 100
Study 16719029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (nutrition and resistance training)
Number of subjects: 100
Study 16719029 — intervention group
Group type: COMPARATOR
Intervention: Attention control plus usual care and general nutrition and exercise advice
Number of subjects: 100
Study 12709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day followed by 400 mg/day)
Number of subjects: 40
Study 12709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil with a 2-day washout period
Number of subjects: 40
Study 12709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil using a taper-down/titrate-up protocol
Number of subjects: 40
Study 12709775 — intervention group
Group type: COMPARATOR
Intervention: Control group (methylphenidate)
Number of subjects: 40
Study 11257323 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 51
Study 11257323 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 51
Study 9356532 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestible cornstarch
Number of subjects: 8
Study 9356532 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially indigestible cornstarch
Number of subjects: 8
Study 8361609 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg quinapril (1 x 20 mg tablet per day)
Number of subjects: 20
Study 8361609 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of nifedipine retard tablets (1 x 20 mg tablet twice daily)
Number of subjects: 20
Study 8361609 — intervention group
Group type: COMPARATOR
Intervention: Both groups (quinapril and nifedipine)
Number of subjects: 20
Study 3740675 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 3363
Study 3740675 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 3363
Study 3740675 — intervention group
Group type: EXPERIMENTAL
Intervention: Any alkylating agent
Number of subjects: 3363
Study 3740675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (general)
Number of subjects: 3363
Study 29658750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousal positive (HAP)
Number of subjects: 100
Study 29658750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousal negative (HAN)
Number of subjects: 100
Study 29658750 — intervention group
Group type: COMPARATOR
Intervention: Low arousal (LA)
Number of subjects: 100
Study 29658750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall emotional arousal conditions (HAP, HAN, LA)
Number of subjects: 100
Study 27270480 — intervention group
Group type: EXPERIMENTAL
Intervention: NA mFOLFOX6 chemotherapy alone (CS group, n = 48)
Number of subjects: 102
Study 27270480 — intervention group
Group type: COMPARATOR
Intervention: NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54)
Number of subjects: 102
Study 25402562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive health education and behavioural intervention
Number of subjects: 474
Study 25402562 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 474
Study 23018169 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education program (group discussion, lectures, pamphlets)
Number of subjects: 105
Study 23018169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study 20565846 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 week tailored exercise programme run by qualified exercise professionals at community sports centres
Number of subjects: 2104
Study 20565846 — intervention group
Group type: COMPARATOR
Intervention: Information booklet on physical activity
Number of subjects: 2104
Study 18298358 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 68
Study 18298358 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 68
Study 18298358 — intervention group
Group type: EXPERIMENTAL
Intervention: No active shoulder control
Number of subjects: 68
Study 18298358 — intervention group
Group type: COMPARATOR
Intervention: Active shoulder control
Number of subjects: 68
Study 15688181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacain
Number of subjects: 100
Study 15688181 — intervention group
Group type: COMPARATOR
Intervention: 1% Mepivacain
Number of subjects: 100
Study 12895689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg/day, n=15)
Number of subjects: 31
Study 12895689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 31
Study 12486467 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensile corset (n = 72)
Number of subjects: 143
Study 12486467 — intervention group
Group type: COMPARATOR
Intervention: Traditional corset (n = 71)
Number of subjects: 143
Study 12486467 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensile corset (n = 30) without central obesity
Number of subjects: 143
Study 9721060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling training program (Group I)
Number of subjects: 38
Study 9721060 — intervention group
Group type: COMPARATOR
Intervention: Cycling and jogging training program (Group II)
Number of subjects: 38
Study 7867237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing Ergometry (RE)
Number of subjects: 10
Study 7867237 — intervention group
Group type: COMPARATOR
Intervention: Cycle Ergometry (CE)
Number of subjects: 10
Study 2910656 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, neomycin, and cefazolin
Number of subjects: 155
Study 2910656 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 155
Study 4928171 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 2
Study 4928171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 2
Study 4928171 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 2
Study 4928171 — intervention group
Group type: COMPARATOR
Intervention: Phenazocine
Number of subjects: 2
Study 31266155 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE (50 mg oleuropein) consumed in capsule form 3 times a day for 1 week
Number of subjects: 11
Study 31266155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn GENEActiv accelerometer
Number of subjects: 89
Study 28501418 — intervention group
Group type: COMPARATOR
Intervention: Hip-worn ActiGraph (GT3X+) accelerometer
Number of subjects: 89
Study 28501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 89
Study 25959529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 37
Study 25959529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24246433 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 357
Study 24246433 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (social network intervention)
Number of subjects: 357
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (Wh, low-viscous liquid)
Number of subjects: 8
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (Cas, high-viscous liquid)
Number of subjects: 8
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein cross-linked with transglutaminase (Cas-TG, rigid gel)
Number of subjects: 8
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (Wh)
Number of subjects: 8
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (Cas)
Number of subjects: 8
Study 21736770 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein cross-linked with transglutaminase (Cas-TG)
Number of subjects: 8
Study 19747429 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Number of subjects: 536
Study 19747429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 16534456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose OPTI‐FREE RepleniSH (test RWD)
Number of subjects: 0
Study 16534456 — intervention group
Group type: COMPARATOR
Intervention: 0.9% unpreserved unit-dose saline (control)
Number of subjects: 0
Study 12723527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone and estrogen (n = 18)
Number of subjects: 45
Study 12723527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (n = 17)
Number of subjects: 45
Study 12723527 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with spontaneous puberty (n = 10)
Number of subjects: 45
Study 10840288 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anger, decreased vigor, increased confusion, negative attitude toward herpes, self-concealment, stress symptoms from genital herpes
Number of subjects: 252
Study 10840288 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anger, negative attitude toward herpes, decreased willingness to share personal information with a stranger
Number of subjects: 252
Study 9044233 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 rpm
Number of subjects: 58
Study 9044233 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 rpm
Number of subjects: 58
Study 8403798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin infusion
Number of subjects: 9
Study 8403798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin combined with loxiglumide
Number of subjects: 9
Study 8403798 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 30219435 — intervention group
Group type: EXPERIMENTAL
Intervention: SE + HIIE
Number of subjects: 9
Study 30219435 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE + SE
Number of subjects: 9
Study 30219435 — intervention group
Group type: COMPARATOR
Intervention: REST
Number of subjects: 9
Study 27418381 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus medication (venlafaxine plus lithium, four continuation ECT treatments over 1 month)
Number of subjects: 120
Study 27418381 — intervention group
Group type: COMPARATOR
Intervention: Medication only (venlafaxine plus lithium over 24 weeks)
Number of subjects: 120
Study 27418381 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus medication
Number of subjects: 120
Study 24871703 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) administration
Number of subjects: 82
Study 24871703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 22310055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or 6 months of neo‐adjuvant androgen deprivation therapy (NADT)
Number of subjects: 802
Study 22310055 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 802
Study 20040034 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating and silanization (n = 8 for each taper angle)
Number of subjects: 32
Study 20040034 — intervention group
Group type: EXPERIMENTAL
Intervention: HF acid etching and silanization (n = 8 for each taper angle)
Number of subjects: 32
Study 18817989 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-expansive respiratory patterns associated to respiratory biofeedback (RBF)
Number of subjects: 60
Study 18817989 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback alone
Number of subjects: 60
Study 15801991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) at 6 weeks
Number of subjects: 37
Study 15801991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) at 12 weeks
Number of subjects: 37
Study 15801991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg-0.8 mg) over three time points
Number of subjects: 37
Study 12464951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B (20 mL of a 100 microg/mL solution twice daily)
Number of subjects: 51
Study 12464951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B
Number of subjects: 51
Study 10451400 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 88
Study 10451400 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented infants
Number of subjects: 88
Study 8540704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus rifampin (n = 10)
Number of subjects: 31
Study 8540704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus vancomycin (n = 10)
Number of subjects: 31
Study 8540704 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone alone (n = 11)
Number of subjects: 31
Study 1721386 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 + OLT
Number of subjects: 0
Study 1721386 — intervention group
Group type: COMPARATOR
Intervention: CyA + OLT
Number of subjects: 0
Study 6285939 — intervention group
Group type: COMPARATOR
Intervention: pivmecillinam
Number of subjects: 30
Study 6285939 — intervention group
Group type: COMPARATOR
Intervention: mecillinam
Number of subjects: 30
Study 31140443 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based internet intervention with peer support
Number of subjects: 25
Study 31140443 — intervention group
Group type: COMPARATOR
Intervention: Individual internet intervention designed to prevent PPD
Number of subjects: 25
Study 28350567 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective repair
Number of subjects: 496
Study 28350567 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 496
Study 26842694 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention (game about alcohol with tailored feedback)
Number of subjects: 2649
Study 26842694 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline questionnaire only)
Number of subjects: 2649
Study 24706596 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time alerts sent to the rapid response team (RRT)
Number of subjects: 571
Study 22671949 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (theory-based interventions, 10 sessions of 45 minutes)
Number of subjects: 441
Study 22671949 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (theory-based interventions)
Number of subjects: 441
Study 22671949 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional group (traditional didactic teaching and drug refusal skills)
Number of subjects: 441
Study 22671949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 441
Study 20642555 — intervention group
Group type: EXPERIMENTAL
Intervention: Woohwangcheongsimwon suspension
Number of subjects: 14
Study 17980221 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions training intervention
Number of subjects: 114
Study 17980221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 15080766 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily for 4 days plus lumiracoxib 400 mg
Number of subjects: 14
Study 15080766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide/magnesium hydroxide antacid plus lumiracoxib 400 mg
Number of subjects: 14
Study 15080766 — intervention group
Group type: COMPARATOR
Intervention: Lumiracoxib 400 mg alone
Number of subjects: 14
Study 12546269 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (Actonel)
Number of subjects: 0
Study 12546269 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 9835826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride/silica dentifrice
Number of subjects: 3
Study 9835826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride/calcium pyrophosphate (positive control) dentifrice
Number of subjects: 3
Study 9835826 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated placebo/calcium pyrophosphate (negative control) dentifrice
Number of subjects: 3
Study 8074020 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine infusion
Number of subjects: 23
Study 8074020 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate infusion
Number of subjects: 23
Study 8074020 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 23
Study 2552552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin administered subcutaneously twice daily (initial dose 100 U anti‐Xa/kg/12 h, adjusted based on anti‐Xa activity)
Number of subjects: 66
Study 2552552 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin administered by continuous infusion (initial dose 240 UI/kg/12 h, adjusted based on APTT)
Number of subjects: 66
Study 1194519 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure plus ego involving instructions
Number of subjects: 36
Study 1194519 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure group
Number of subjects: 36
Study 1194519 — intervention group
Group type: COMPARATOR
Intervention: Test retest control group
Number of subjects: 36
Study 30910410 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 34
Study 30910410 — intervention group
Group type: COMPARATOR
Intervention: Control (socket sutured primarily)
Number of subjects: 34
Study 29149418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Trendelenburg position (LTP)
Number of subjects: 395
Study 29149418 — intervention group
Group type: COMPARATOR
Intervention: Semirecumbent position (SRP)
Number of subjects: 395
Study 25719937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (FAI)
Number of subjects: 641
Study 25719937 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 641
Study 24356595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy during the DCCT
Number of subjects: 0
Study 22844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) challenge
Number of subjects: 42
Study 22844471 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fat (PUFA) challenge
Number of subjects: 42
Study 22844471 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat (SFA) challenge
Number of subjects: 42
Study 22844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese and obese diabetic subjects
Number of subjects: 42
Study 19678782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 45
Study 19678782 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 45
Study 21352112 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment (assertive community treatment with family involvement and social skills training)
Number of subjects: 547
Study 21352112 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (contact with a community mental health centre)
Number of subjects: 547
Study 21352112 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547
Study 15668841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 degrees C increase in incubator temperature (T + 1 degrees C)
Number of subjects: 20
Study 15668841 — intervention group
Group type: COMPARATOR
Intervention: 1 degrees C decrease in incubator temperature (T - 1 degrees C)
Number of subjects: 20
Study 12375299 — intervention group
Group type: EXPERIMENTAL
Intervention: New antidepressant (dose escalation)
Number of subjects: 10
Study 10447621 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spontaneous subcapital femoral neck fractures (n=7)
Number of subjects: 274
Study 10447621 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=267)
Number of subjects: 274
Study 8665883 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 75 mg
Number of subjects: 50
Study 8665883 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg
Number of subjects: 50
Study 2351365 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam pretreatment
Number of subjects: 0
Study 2351365 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study 94225 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 5% lidocaine and 5% prilocaine
Number of subjects: 17
Study 94225 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 17
Study 94225 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 5% lidocaine and 5% prilocaine used daily for 3-4 weeks
Number of subjects: 17
Study 30368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-based categories
Number of subjects: 0
Study 30368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-integration categories
Number of subjects: 0
Study 30368558 — intervention group
Group type: EXPERIMENTAL
Intervention: YES/NO learning paradigm
Number of subjects: 0
Study 30368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguous, semi-contiguous, non-contiguous categories
Number of subjects: 0
Study 31172520 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Deliberation (CD)
Number of subjects: 707
Study 31172520 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizens' Panel (CP)
Number of subjects: 707
Study 31172520 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 707
Study 27423432 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (162 mg/d)
Number of subjects: 68
Study 27423432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24734909 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft
Number of subjects: 15
Study 24734909 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen bone allograft
Number of subjects: 15